Disparities in Maternal-Infant Drug Testing
More infants who were exposed to strong agonists and opioids with long half-lives, including methadone, developed neonatal opioid withdrawal syndrome.
More infants who were exposed to strong agonists and opioids with long half-lives, including methadone, developed neonatal opioid withdrawal syndrome.
Mandatory warning sign policies were not associated with reduced cannabis use during pregnancy, nor did they shift opinions regarding risk among those using cannabis prior to pregnancy.
At this point, the medical use of cannabis is legal in 37 states and the District of Columbia (D.C.). The recreational use of cannabis has been legalized in 21 states and D.C. The downstream effect [...]
A large cohort study from Canada has observed that cannabis use during pregnancy was associated with increased risk of preterm birth, low birth weight and small-for-gestational age.
Treatment with buprenorphine versus methadone during pregnancy is associated with lower risk of preterm birth, low birth weight, small size for gestational age, and NAS.
Opioid use during pregnancy co-occurs with other variables that are associated with worse outcomes in children, specifically maternal depression and the use of alcohol, tobacco, and other drugs.
More infants who were exposed to strong agonists and opioids with long half-lives, including methadone, developed neonatal opioid withdrawal syndrome.
Prenatal cannabis exposure was associated with persisting vulnerability to psychopathology throughout early adolescence.
Prenatal opioid use is associated with increased maternal and infant mortality, prematurity, and poor neonatal outcomes.
Cannabis use, as well as use of benzodiazepines and sedative-hypnotic medications, was more common in women with depression.